Disease · MONDO_0026045
Trials33
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 20 of 33
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03677401 | Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis | Phase 3 | 295 | 2020-10-28 | Pruritus, Prurigo Nodularis | SERLOPITANT | Its record names the disease | ClinicalTrials.gov |
| NCT04501666 | Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) | Phase 3 | 286 | 2024-07-10 | Prurigo Nodularis | NEMOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04501679 | A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) | Phase 3 | 274 | 2024-07-10 | Prurigo Nodularis | NEMOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03816891 | Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis | Phase 2 | 240 | 2026-01-13 | Prurigo Nodularis, Pruritis | VIXARELIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05755438 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) | Phase 3 | 204 | 2025-11-14 | Prurigo | RUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT05764161 | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) | Phase 3 | 190 | 2025-11-24 | Prurigo Nodularis | RUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04202679 | Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2) | Phase 3 | 160 | 2022-09-28 | Neurodermatitis | DUPILUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04183335 | Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME) | Phase 3 | 151 | 2022-12-12 | Neurodermatitis | DUPILUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05061693 | A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | Phase 2 | 146 | 2024-08-27 | Prurigo Nodularis | POVORCITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02196324 | A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN) | Phase 2 | 128 | 2021-02-02 | Prurigo Nodularis | SERLOPITANT | Its record names the disease | ClinicalTrials.gov |
| NCT03181503 | Safety and Efficacy of Nemolizumab in PN | Phase 2 | 70 | 2020-02-19 | Prurigo Nodularis | NEMOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02174419 | Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis | Phase 2/3 | 62 | 2020-08-21 | Prurigo Nodularis, Nodularis Prurigo, Prurigo, Pruritus | NALBUPHINE | Its record names the disease | ClinicalTrials.gov |
| NCT02174432 | Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis | Phase 2/3 | 36 | 2020-10-23 | Prurigo Nodularis, Nodularis Prurigo, Prurigo | NALBUPHINE | Its record names the disease | ClinicalTrials.gov |
| NCT05052983 | A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis | Phase 3 | 34 | 2024-10-08 | Prurigo Nodularis | NEMOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05038982 | Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin | Phase 2 | 20 | 2023-07-03 | Prurigo Nodularis, Pruritus, Chronic Pruritus, Chronic Prurigo, Skin Diseases | ABROCITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04204616 | A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) | Phase 3 | 500 | Prurigo Nodularis | NEMOLIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT06527404 | A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis | Phase 3 | 469 | Prurigo Nodularis | ROCATINLIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT06516952 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | Phase 3 | 349 | Prurigo Nodularis | POVORCITINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT06516965 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | Phase 3 | 346 | Prurigo Nodularis | POVORCITINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT06424470 | Study on the Treatment of Prurigo Nodularis With Stapokibart Injection | Phase 3 | 200 | Prurigo Nodularis | STAPOKIBART | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0026045/trials